A Phase 1, Dose Escalation, Safety and Tolerability Study of NX-2127, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed/Refractory B-cell Malignancies
Latest Information Update: 15 Oct 2024
At a glance
- Drugs NX-2127 (Primary)
- Indications B-cell leukaemia; B-cell lymphoma; Chronic lymphocytic leukaemia; CNS cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
- Sponsors Nurix
- 11 Oct 2024 According to a Nurix media release, clinical updates on this trial are anticipated in 2025.
- 11 Sep 2024 Planned number of patients changed from 160 to 248.
- 26 Jul 2024 Planned End Date changed from 1 Dec 2025 to 1 Dec 2026.